Hormone-dependent prostate cancer
Not recruitingStudy on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer
Study on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer
- Disease:Hormone-dependent prostate cancer
- Substances:18F-Psma-1007Lutetium (177Lu) Vipivotide Tetraxetan
The Netherlands- Participants:18–64 years · 65+ years
- Substances:18F-Psma-1007
- Sponsor:Stichting Radboud University Medical Center










